Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
PCVX logo PCVX
Upturn stock ratingUpturn stock rating
PCVX logo

Vaxcyte Inc (PCVX)

Upturn stock ratingUpturn stock rating
$31.43
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: PCVX (2-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

Number of Analysts

rating

10 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $114.88

1 Year Target Price $114.88

Analysts Price Target For last 52 week
$114.88 Target price
52w Low $27.66
Current$31.43
52w High $121.06

Analysis of Past Performance

Type Stock
Historic Profit 28.81%
Avg. Invested days 47
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 3.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 4.08B USD
Price to earnings Ratio -
1Y Target Price 114.88
Price to earnings Ratio -
1Y Target Price 114.88
Volume (30-day avg) 10
Beta 1.21
52 Weeks Range 27.66 - 121.06
Updated Date 08/15/2025
52 Weeks Range 27.66 - 121.06
Updated Date 08/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -4.11

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date 2025-08-06
When -
Estimate -1.17
Actual -1.22

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -16.44%
Return on Equity (TTM) -21.65%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 2504766047
Price to Sales(TTM) -
Enterprise Value 2504766047
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -14.43
Shares Outstanding 129823000
Shares Floating 116744950
Shares Outstanding 129823000
Shares Floating 116744950
Percent Insiders 0.67
Percent Institutions 113.09

ai summary icon Upturn AI SWOT

Vaxcyte Inc

stock logo

Company Overview

overview logo History and Background

Vaxcyte, Inc. was founded in 2013. It is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of infectious diseases.

business area logo Core Business Areas

  • Vaccine Development: Vaxcyte focuses on developing novel and improved vaccines using its cell-free protein synthesis platform. Its primary focus is on preventing or treating infectious diseases.

leadership logo Leadership and Structure

Grant Pickering is the CEO. The company has a board of directors and a leadership team focused on research, development, and commercialization.

Top Products and Market Share

overview logo Key Offerings

  • PCV20: Vaxcyte's lead candidate is PCV20, a 20-valent pneumococcal conjugate vaccine targeting Streptococcus pneumoniae. Market share is currently zero, as it's in development. Competitors include Pfizer (Prevnar 20) and Merck.
  • Vaxcyte's second program: is VAX-A1, a vaccine to prevent Group A Strep. Market share is currently zero, as it's in development. Competitors include multiple firms developing Group A strep vaccines.

Market Dynamics

industry overview logo Industry Overview

The vaccine market is substantial and growing, driven by increased awareness of preventative healthcare and emerging infectious diseases. Advancements in vaccine technology and manufacturing are key trends.

Positioning

Vaxcyte aims to compete by developing more effective and convenient vaccines using its cell-free technology. Its competitive advantage lies in potentially improved immunogenicity and manufacturability.

Total Addressable Market (TAM)

The pneumococcal vaccine market is estimated to be multi-billion dollar. Vaxcyte's PCV20 targets a significant portion of this TAM. Group A Strep is also multi-billion dollar market.

Upturn SWOT Analysis

Strengths

  • Cell-free protein synthesis platform
  • Strong intellectual property portfolio
  • Experienced management team
  • Lead candidate PCV20 in clinical trials

Weaknesses

  • No currently marketed products
  • Reliance on successful clinical trial outcomes
  • Limited financial resources compared to large pharma
  • High R&D costs

Opportunities

  • Partnerships with larger pharmaceutical companies
  • Expansion into new vaccine targets
  • Favorable regulatory environment
  • Growing demand for preventative healthcare

Threats

  • Clinical trial failures
  • Competition from established vaccine manufacturers
  • Patent challenges
  • Changes in regulatory landscape

Competitors and Market Share

competitor logo Key Competitors

  • PFE
  • MRK

Competitive Landscape

Vaxcyte aims to differentiate itself with potentially improved vaccines. Competes with large, established players like Pfizer and Merck.

Growth Trajectory and Initiatives

Historical Growth: Growth is primarily driven by clinical trial progress and pipeline development.

Future Projections: Future growth depends on successful clinical trial outcomes and potential commercialization of PCV20 and other vaccine candidates.

Recent Initiatives: Advancing PCV20 through clinical trials, expanding pipeline with new vaccine targets, securing partnerships.

Summary

Vaxcyte is a clinical-stage company with a promising cell-free protein synthesis platform, driving its vaccine candidates forward. Its success hinges on positive clinical trial outcomes and competition in the vaccine industry is fierce, especially from established giants. Vaxcyte needs to carefully manage its resources and leverage strategic partnerships to maintain its trajectory.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Vaxcyte's website
  • SEC filings
  • Analyst reports
  • Market research reports

Disclaimers:

This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Vaxcyte Inc

Exchange NASDAQ
Headquaters San Carlos, CA, United States
IPO Launch date 2020-06-12
Co-Founder, CEO & Director Mr. Grant E. Pickering M.B.A.
Sector Healthcare
Industry Biotechnology
Full time employees 414
Full time employees 414

Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; and VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.